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A B S T R A C T
Gestational depression is detrimental to the health of the mother and the offspring and 
contributes to the appearance of depressive and anxiety symptoms during the postnatal 
period. Traditional antidepressants have undesirable side effects when utilised during 
gestation, but Hypericum perforatum has been characterised as an efficient and safe 
antidepressant that prevents the recurrence of symptoms. This study verified the effects of 
Hypericum perforatum on the behaviour of Wistar rats that were treated during gestation and 
evaluated 10 and 60 days post-treatment. Pregnant Wistar rats were divided into four groups 
of ten animals each: one control group that received distilled water and three treatment 
groups that were treated orally with 36, 72 or 144 mg/kg Hypericum perforatum extract. At 
10 and 60 days after parturition and post-treatment, the rats were submitted to the hole-
board, the tail suspension, and the forced swim tests. The animals treated with 144 mg/
kg Hypericum perforatum exhibited greater head-dipping activity in the hole-board test and 
reduced immobility in the tail suspension and forced swim tests, suggesting less anxiety 
and depression 10 and 60 days post-treatment. The results indicated that treating rats with 
Hypericum perforatum during the gestational period decreased depressive behaviour and 
anxiety 10 and 60 days post-treatment.
© 2013 Elsevier Editora Ltda. 
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Introduction
Depression is a worldwide public health problem and is 
considered one of the leading causes of disability. In 2001, 
approximately 154 million people were affected by depression, 
and it is estimated that it will become the most common illness 
in the world by 2030 (WHO, 2001). In women, depression is even 
more disturbing when it occurs during gestation; according to 
certain authors, the neuroendocrine changes that occur during 
gestation favour the development of depressive disorders 
(Campagne, 2004; Steiner et al., 2003). 
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Gestat ional  depress ion modif ies  the  maternal 
environment and severely damages the health of the 
mother and the offspring (Field et al., 2008; Oberlander et 
al., 2006; Rosen et al., 2007). The occurrence of a depressive 
disorder during gestation can contribute to mood and 
anxiety disorders during the postpartum period because 
symptoms expressed during gestation can become 
exacerbated postpartum (Bloch et al., 2003; Brockington, 
2004; Riecher-rössler and Steiner, 2005; Steiner et al., 2003). 
Because of this, it is imperative to identify an efficient 
treatment for depression that can be safely administered 
to pregnant women and that decreases both the recurrence 
of symptoms and the risk of mood and anxiety disorders in 
the puerperium.
Traditional antidepressants exert diverse side effects 
and can be toxic to the child when taken during gestation. 
Furthermore, they are found in the placenta, amniotic fluid 
and breast milk, suggesting that they should be utilised 
cautiously by pregnant women (Dodd et al., 2006; Hostetter 
et al., 2000). Sufficient data in the literature have provided 
evidence that there is no relationship between the use of 
these medications for the treatment of gestational depression 
and a reduction in the recurrence of depressive and anxiety 
symptoms in the puerperal period (Dodd et al., 2006; Newport 
et al., 2001).
Hypericum perforatum L., Hypericaceae, commonly known 
as hyperic or St. John’s wort, is a proven antidepressant that 
has no indications of severe side effects. In mice treated 
during gestation, there is no toxicity to the offspring and no 
interference with motor and behavioural development, as 
assessed immediately after weaning (Bahls, 2001; Brattstrom, 
2009; Cada et al., 2001; Nepomuceno et al., 2005). In addition, 
H. perforatum (HP) has a long-lasting effect and prevents the 
recurrence of symptoms even after the treatment has ended, 
indicating that HP should be regarded as an efficient and 
safe alternative to treat depression during gestation (Singer 
et al., 2011). Phytochemical studies have characterised the 
presence of various substances in HP, including flavonoids, 
naphthodianthrones (such as hypericin) and hyperforin, a 
prenylated phloroglucinol derivative that is believed to be the 
primary active constituent responsible for the antidepressant 
and anxiolytic properties of the herbal extracts (Singer et al., 
1999). 
Based on the antidepressant activity of HP, its possible 
long-lasting effects and its ability to prevent the recurrence of 
symptoms, this study was designed to evaluate the postpartum 
behaviour of Wistar rats 10 and 60 days after the end of HP 
treatment during gestation.
Materials and methods
Plant material
A standard dry extract of Hypericum perforatum  L. , 
Hypericaceae, containing 0.3% hypericin was imported 
from China, identified by the deposit number 20100913, 
and prepared by Mbpharma Manipulações LTDA as lot 
10124778E.
Assays
Pregnant Wistar rats (Rattus norvegicus Berkenhout, 1769) 
were obtained from the vivarium of the Centro de Biologia 
da Reprodução, Federal University of Juiz de Fora, at 90 days 
of age and were housed in polypropylene cages (40 x 30 x 16 
cm) containing five animals each. The animals were housed 
under standard laboratory conditions, with a controlled 
temperature of 23 ± 2ºC and a 12 h light/dark photoperiod, 
with the light period beginning at 6 AM. The dams had free 
access to water and were fed rat chow pellets (Purina). They 
were deprived of feed 60 min before the beginning of the tests. 
After parturition, each female and her offspring were placed 
in individual cages and then separated after weaning.
The dams were distributed into four groups of ten pregnant 
rats each: three treatment groups and one control group. 
During gestation, the rats in the treatment groups received 
oral (gavage) doses of the aqueous extract of HP at 36 mg/
kg (T1), 72 mg/kg (T2), and 144 mg/kg (T3) once daily. The 
volume ranged from 0.4 to 0.6 ml, depending on the weight 
of the pregnant rat. The rats in the control group (C) received 
distilled water during the same time period. The doses were 
chosen based on information available in the literature. HP 
action in the rat central nervous system (CNS) was previously 
observed at doses higher than 30 mg/kg (Crupi et al., 2011).
The dams were examined 10 and 60 days after parturition. 
Ten days after the end of the treatment, the animals were 
submitted to the hole-board test to evaluate anxiety and to 
the tail suspension test to evaluate depression. Sixty days after 
parturition, the rats were once again submitted to the same tests, 
along with the forced swim test to confirm depressive behaviour. 
The forced swim test was not performed 10 days after parturition 
to avoid any interference of hypothermia with breast-feeding. 
The rats were weighed daily during the treatment period.
Hole-board test
The hole-board test is frequently utilised to screen for effects 
of psychotropic drugs on the exploration and spatial learning 
behaviour of a rodent. When placed in a new environment, 
the natural tendency of an animal is to explore the holes by 
plunging its head in and out of the hole a few times. This test 
enables an assessment of the effects of psychotropic drugs 
on head dipping and exploration activity and is based on the 
assumption that head-dipping is inversely proportional to 
anxiety (Boisser et al., 1976; Carlini and Mendes, 2001; Mattei 
and Carlini, 1995; Saitoh et al., 2006). In addition, locomotor 
activity (movements with dislocation) and stereotypical and 
exploratory movements in the holes are also parameters 
that reflect the anxiety level (Casarrubea et al., 2009). 
The hole-board apparatus (model LE 8811, from Panlab 
s.l) consisted of a transparent acrylic box with sixteen 
equidistant holes on the surface and photoelectric cells 
on the side plates that were capable of conducting an 
automated reading animal movement, thereby preventing 
possible human error during observation. Each animal was 
placed in the centre of the plate once and was observed 
for five minutes. The number of head-dips into the holes, 
the locomotor activity (displacement), and the stereotypical 
movements were registered. 
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Tail suspension test
The tail suspension test was described by Steru et al. (1985) 
and is widely utilised in preclinical studies to evaluate the 
antidepressant potential of novel compounds. This test is 
based on the behavioural response of rodents to a stressful 
situation that is perceived as hopeless; animals subjected to 
the short-term, inescapable stress of being suspended by their 
tail develop an immobile posture. Antidepressant medications 
reverse the immobility and promote escape-related behaviour. 
The animals were individually suspended by the tail at a height 
of 50 cm for five min, and depression was measured based 
on immobility. Increased total immobility time and a shorter 
duration of attempting to escape represent more intense 
depressive behaviour (Teixeira-Silva et al., 2006).
Forced swim test
The forced swim test described by Porsolt et al. (1977) is one 
of the most utilised methods for screening antidepressants. 
This test is based on the assumption that animals try to escape 
from an aversive stimulus, providing information about their 
emotional status. The rats underwent a pre-test protocol: 
they were individually forced to swim in polypropylene cages 
(60 × 40 × 40 cm) containing water at a temperature of 25 ± 1° C 
for 15 min as the dangerous situation. The data from this phase 
were not included in the statistical analysis. On the next day, 
the animals were placed in a transparent glass cylinder filled 
with water for 5 min and forced to swim. Their behaviour was 
recorded by registering the time taken by the animal to stop 
struggling and swimming (latency time) as well as the duration 
of immobility. An increased immobility time during this test is 
an accurate indication of the effects of antidepressants (Carlini 
and Mendes, 2001). After each trial, the water was changed.
This project was approved by the Ethical Committee in 
Animal Experimentation of the Universidade Federal de Juiz 
de Fora (protocol number 003/2011).
Statistical analysis
One-way Analysis of Variance (ANOVA) was utilised for 
statistical comparisons of the differences between the test 
groups (α = 0.05), and the results were expressed as the mean 
± standard error for n = 10 observations. For the in vivo studies, 
n represented the number of animals studied. Significant 
interactions were analysed using post-hoc ANOVA with an 
adjusted p value (Sokal and Rohlf, 1995). 
Results
No significant changes in the weight of the control and 
HP-treated animals were observed during gestation. In 
the hole-board test, the average head-dipping activity was 
considerably higher 10 and 60 days after parturition in animals 
treated with 144 mg/kg HP extract and 60 days after parturition 
in animals treated with 72 mg/kg HP extract compared with 
the average head-dipping activity of control animals (Fig. 1). 
Ten days after parturition, the average amount of locomotor 
activity (movements with dislocation) was considerably 
higher and the average number of stereotypical movements 
was significantly lower in animals treated with 144 mg/kg HP 
compared with control animals (Fig. 2). The average number 
of stereotypical movements was also lower sixty days after 
parturition in animals treated with 144 mg/kg HP (Fig. 3).
In the tail suspension test, the animals treated with 144 mg/
kg HP extract exhibited a significant increase in the latency 
time and a significant reduction in the total immobility time 
at both ten and sixty days post-treatment. The animals that 
received 72 mg/kg HP had a statistically lower total immobility 
time than the control animals at the sixty-day evaluation (Figs. 
4 and 5).
In the forced swim test, the average latency time for 
immobility was considerably higher in animals treated with 
72 or 144 mg/kg HP extract, whereas the total immobility time 
was considerably lower in these same animals (Fig. 6).
Fig. 1 - The number of head-dips by control and HP-treated 
rats in the hole-board test. The data are presented as the 
average ± standard deviation (n = 10; * p < 0.05; ** p < 0.001).
Fig. 2 - The amount of locomotor activity and number of 
stereotypical movements by the control and HP-treated rats 
during the spontaneous activity test 10 days post-treatment. 
The data are presented as the average ± standard deviation  
(n = 10; * p < 0.05; ** p < 0.01).
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Discussion
Any treatment that might cause toxicity must be utilised 
with restrictions or should not be prescribed during gestation. 
Body weight reductions in treated animals are indicative of 
organismal toxicity (Hiremath et al., 1997); however, alterations 
in food intake, and consequently in body weight, may also 
indicate a depressive episode (Beck and Brad, 2008; Chahoud 
et al., 1999). In this study, no significant differences in body 
weight were observed in rats treated with HP during gestation, 
suggesting that this compound was not toxic (Nepomuceno 
et al., 2005).
Gestational depressive disorders can lead to the 
manifestation of mood and anxiety disorders during the 
postpartum period, with an intensification of anxiety 
symptoms (Riecher-rössler and Steiner, 2005; Schmidt et 
al., 1997). Nonetheless, these symptoms, when secondary 
to depression, tend to disappear after treating the disorder 
(Ribeiro, 2007). Therefore, the evaluation of depressive and 
anxiety behaviours may be helpful for the diagnosis, treatment, 
and monitoring of depression. 
In the hole-board test, increased animal motion and 
head-dipping activity indicate greater exploratory behaviour, 
whereas decreased stereotypical movements reflect the fear of 
the animal in the unfamiliar environment. All these behaviours 
reflect less anxiety. Therefore, the parameters examined 
in this study suggested that the highest dose of HP extract 
(144 mg/kg), when administered during gestation and evaluated 
ten and sixty days post-treatment, exerted an anxiolytic effect 
in the animals as evidenced by their increased locomotor and 
head-dipping activity and reduced stereotypical movements 
(Carlini and Mendes, 2001).
In preclinical studies evaluating the potential antidepressant 
properties of natural or synthetic substances, the forced swim 
and the tail suspension tests have been utilised to assess the 
emotional status of animals via behavioural despair (Almeida, 
2006). In this study, the increased latency time and reduced 
immobility suggested less depression in animals treated with 
the two higher doses of HP extract (72 and 144 mg/kg) and 
evaluated ten and sixty days post-treatment. 
The reduced depression and anxiety in the post-partum 
period in rats treated during gestation confirmed the chronicity 
of the effects of HP. Patients treated with HP presented with 
fewer depressive symptoms and experienced a longer time to 
recurrence of such symptoms compared with patients treated 
with citalopram, a selective serotonin reuptake inhibitor 
that is traditionally used to treat depression. On average, 
the symptoms reappeared 1817 days after terminating the 
treatment (Singer et al., 2011). 
HP primarily acts by inhibiting the reabsorption of the 
neurotransmitters serotonin, noradrenaline, and dopamine. 
Therefore, the increased concentration of these substances in 
the synaptic cleft justifies the antidepressant effects. When 
HP is used for a long time, adaptations occur in intracellular 
messengers and receptors involved in neurotransmitter activity 
(Franklin, 2003; Ruedeberg et al., 2010) and in hippocampal 
neurons (Crupi et al., 2011). These data explain the effects 
observed in this study even after the treatment had ended.
Fig. 3 - The amount of locomotor activity and the number of 
stereotypical movements by the animals during the sponta-
neous activity test 60 days post-treatment. The data are pre-
sented as the average ± standard deviation (n = 10; * p < 0.05).
Fig. 4 - The latency time (s) to initiate immobility and 
the total immobility time during the tail suspension test 
in control and HP-treated rats evaluated 10 days after 
parturition. The data are presented as the average ± standard 
deviation (n = 10; * p < 0,01; ** p < 0,001).
Fig. 5 - The latency time (s) to initiate immobility and 
the total immobility time during the tail suspension test 
in control and HP-treated rats evaluated 60 days after 
parturition. The data are presented as the average ± standard 
deviation (n = 10; * p < 0.05; ** p < 0.001).
Fig. 6 - The latency time (s) to initiate immobility and the total 
immobility time during the forced swim test in control and 
HP-treated rats evaluated 60 days after parturition. The data are 
presented as the average ± standard deviation (n = 10; * p < 0.05;  
** p < 0.01; *** p < 0.001).
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The results obtained in this study demonstrated that 72 
and 144 mg/kg HP extract interfered with animal behaviour, 
even ten and sixty days post-treatment, thereby providing 
further support for its chronic effects. The results suggested 
that treating rats during gestation with HP inhibited the 
development of post-partum depressive and anxiety 
symptoms, which are often initiated by depression during 
gestation. Nonetheless, more studies are necessary to confirm 
the effects and the mechanisms of action of HP.
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